Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™
February 01, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
January 31, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
January 18, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
January 05, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
December 29, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
December 20, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
December 15, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
November 22, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
November 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
October 28, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
September 07, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Present at September Healthcare Conferences
September 01, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
August 31, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
August 31, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
August 25, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
August 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
August 09, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
July 28, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
June 24, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
June 17, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
May 26, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 11, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Reports First Quarter 2021 Results
May 10, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan
May 10, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors
May 03, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals Announces TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) Formulation, in Combination with Rituximab for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Receives PMDA Approval in Japan
April 30, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Eagle Pharmaceuticals to Host First Quarter 2021 Financial Results on May 10, 2021
April 29, 2021
From
Eagle Pharmaceuticals, Inc.
Via
Business Wire
Tickers
EGRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.